Key result
Bioprosthetic tricuspid valve replacement for severe tricuspid endocarditis resulted in 0% early 30-day hospital mortality and 100% freedom from cardiac death at nine years.
Why the study?
Does bioprosthetic tricuspid valve replacement provide acceptable outcomes in patients with severe tricuspid endocarditis due to infected endocardial pacemaker leads?
Observational (n=26)
Does bioprosthetic tricuspid valve replacement provide acceptable outcomes in patients with severe tricuspid endocarditis due to infected endocardial pacemaker leads?
Bioprosthetic tricuspid valve replacement is a safe and durable option for patients with severe tricuspid endocarditis secondary to infected pacemaker leads, with excellent long-term freedom from cardiac death.
May support use in refractory pacemaker lead cases; leaves open need for larger studies to confirm durability.
BACKGROUND: The purpose of this study was to present outcomes of bioprosthetic tricuspid valve replacement (TVR) in patients with tricuspid valve infective endocarditis (TVIE). METHODS: From October 2001 to December 2015, 26 patients underwent a bioprosthetic TVR due to severe TVIE after endocardial pacemaker implantation. RESULTS: Staphylococcus species and Streptococcus species were the predominant microorganisms. Early 30-day hospital mortality was 0 (0%). There were three late deaths (11.5%), none cardiac related. At nine years, freedom from cardiac death was 100%. Mean follow-up was 5.7 ± 4.1 years (range, 1.3-14.2 years). There were two cases (7.7%) of cardiac redo operations related to recurrent infection. At nine years, freedom from valve-related redo operation was 92.3%. There was no thrombosis-embolism, bleeding, or other valve-related events. No peri-valve leak or vegetation was seen on the last echocardiographic examination. CONCLUSIONS: Bioprosthetic TVR can be performed with acceptable morbidity and mortality in severe tricuspid endocarditis due to infected endocardial pacemaker leads.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2016) conducted an observational in Tricuspid valve infective endocarditis secondary to infected endocardial pacemaker leads (n=26). Bioprosthetic tricuspid valve replacement was evaluated on Early 30-day hospital mortality. Bioprosthetic tricuspid valve replacement for severe tricuspid endocarditis resulted in 0% early 30-day hospital mortality and 100% freedom from cardiac death at nine years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: